{"id":63529,"date":"2026-04-20T14:16:13","date_gmt":"2026-04-20T06:16:13","guid":{"rendered":"https:\/\/flcube.com\/?p=63529"},"modified":"2026-04-20T14:19:09","modified_gmt":"2026-04-20T06:19:09","slug":"sino-biopharmaceutical-reports-55-response-rate-for-pd-1-vegf-bispecific-lm-299-mk-2010-in-nsclc-at-aacr-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63529","title":{"rendered":"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\/VEGF Bispecific LM-299\/MK-2010 in NSCLC at AACR 2026"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) presented preliminary clinical data for <strong>LM-299\/MK-2010<\/strong>, a <strong>PD-1\/VEGF bispecific antibody<\/strong> (BsAb) co-developed by its subsidiary <strong>LaNova Medicines Ltd<\/strong> and <strong>Merck, Sharp &amp; Dohme Inc.<\/strong> (MSD; <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>), at the <strong>2026 American Association for Cancer Research<\/strong> (AACR) Annual Meeting. The data demonstrate encouraging antitumor activity and a manageable safety profile in <strong>non-small cell lung cancer<\/strong> (NSCLC) patients, validating MSD&#8217;s $3.3 billion licensing investment made in 2024.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-context\">Deal Structure &amp; Strategic Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Lead Developer<\/strong><\/td><td>LaNova Medicines Ltd (subsidiary of Sino Biopharmaceutical)<\/td><\/tr><tr><td><strong>Global Partner<\/strong><\/td><td>Merck, Sharp &amp; Dohme Inc. (NYSE: MRK)<\/td><\/tr><tr><td><strong>Licensing Deal<\/strong><\/td><td>$3.3 billion agreement (2024)<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive global development, manufacturing, and commercialization rights to LM-299\/MK-2010<\/td><\/tr><tr><td><strong>Acquisition Timeline<\/strong><\/td><td>Sino Bio acquired LaNova in July 2025, securing the product pipeline<\/td><\/tr><tr><td><strong>Clinical Presentation<\/strong><\/td><td>AACR Annual Meeting 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design-amp-patient-population\">Clinical Trial Design &amp; Patient Population<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Phase:<\/strong> Phase I\/II clinical trial<\/li>\n\n\n\n<li><strong>Total Enrolled:<\/strong> 112 patients receiving MK-2010\/LM-299<\/li>\n\n\n\n<li><strong>Dose-Escalation Cohort:<\/strong> 40 patients<\/li>\n\n\n\n<li><strong>NSCLC Expansion Cohort:<\/strong> 72 patients<\/li>\n\n\n\n<li><strong>Dosing Regimens:<\/strong> 20 mg\/kg Q3W and 30 mg\/kg Q3W groups<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Treatment-na\u00efve NSCLC patients in expansion cohort<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-profile-manageable-toxicity-profile\">Safety Profile \u2013 Manageable Toxicity Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Safety Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Grade 5 TRAEs<\/strong><\/td><td>None observed<\/td><\/tr><tr><td><strong>Treatment Discontinuations<\/strong><\/td><td>1 patient (dose-escalation cohort)<\/td><\/tr><tr><td><strong>Grade 3-4 TRAEs<\/strong> (NSCLC cohort)<\/td><td>17\u201327% incidence<\/td><\/tr><tr><td><strong>Treatment-Related Deaths<\/strong><\/td><td>None reported<\/td><\/tr><tr><td><strong>VEGF Inhibitor Toxicities<\/strong><\/td><td>Predominantly \u2264 grade 3, manageable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The bispecific antibody demonstrated a <strong>favorable safety profile<\/strong> consistent with established PD-1 and VEGF inhibitor classes, with no unexpected safety signals identified.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-efficacy-results-promising-antitumor-activity\">Efficacy Results \u2013 Promising Antitumor Activity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Efficacy Endpoint<\/th><th>20 mg\/kg Q3W<\/th><th>30 mg\/kg Q3W<\/th><\/tr><\/thead><tbody><tr><td><strong>Unconfirmed ORR<\/strong> (treatment-na\u00efve NSCLC)<\/td><td><strong>55%<\/strong><\/td><td><strong>44%<\/strong><\/td><\/tr><tr><td><strong>Pharmacokinetic Half-life<\/strong><\/td><td><strong>9.5\u201312.6 days<\/strong> (mean across cohorts)<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The <strong>55% objective response rate<\/strong> in the 20 mg\/kg cohort represents competitive efficacy compared to existing PD-1 monotherapies and combination regimens in first-line NSCLC settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications-amp-competitive-positioning\">Market Implications &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NSCLC Market Opportunity:<\/strong> Global NSCLC therapeutics market projected to reach <strong>$45 billion by 2030<\/strong>, with bispecific antibodies emerging as a key growth segment.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> LM-299\/MK-2010 competes with other PD-1\/VEGF bispecifics including Roche&#8217;s faricimab and emerging candidates from AstraZeneca and BeiGene.<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Given MSD&#8217;s $3.3 billion upfront commitment and global rights, peak sales projections could exceed <strong>$2 billion annually<\/strong> if Phase III confirms current efficacy signals.<\/li>\n\n\n\n<li><strong>Strategic Value for Sino Bio:<\/strong> The acquisition of LaNova has proven prescient, providing Sino Biopharmaceutical with significant milestone payments and royalty streams from one of the most promising bispecific programs in oncology.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for LM-299\/MK-2010. Actual results may differ due to risks including Phase III trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041900002_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026041900002_c.\"><\/object><a id=\"wp-block-file--media-714f7477-7ab5-499c-91e6-7c0c426ab6ed\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041900002_c.pdf\">2026041900002_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041900002_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-714f7477-7ab5-499c-91e6-7c0c426ab6ed\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299\/MK-2010, a PD-1\/VEGF bispecific antibody&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,17,908,1376,2675,176,28,903,313],"class_list":["post-63529","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-clinical-trial-results","tag-hkg-1177","tag-lanova-medicines","tag-merck-sharp-dohme","tag-msd","tag-multi-specific-antibodies","tag-nyse-mrk","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical Reports 55% Response Rate for PD-1\/VEGF Bispecific LM-299\/MK-2010 in NSCLC at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299\/MK-2010, a PD-1\/VEGF bispecific antibody (BsAb) co-developed by its subsidiary LaNova Medicines Ltd and Merck, Sharp &amp; Dohme Inc. (MSD; NYSE: MRK), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate encouraging antitumor activity and a manageable safety profile in non-small cell lung cancer (NSCLC) patients, validating MSD&#039;s $3.3 billion licensing investment made in 2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63529\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\/VEGF Bispecific LM-299\/MK-2010 in NSCLC at AACR 2026\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299\/MK-2010, a PD-1\/VEGF bispecific antibody (BsAb) co-developed by its subsidiary LaNova Medicines Ltd and Merck, Sharp &amp; Dohme Inc. (MSD; NYSE: MRK), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate encouraging antitumor activity and a manageable safety profile in non-small cell lung cancer (NSCLC) patients, validating MSD&#039;s $3.3 billion licensing investment made in 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63529\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T06:16:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-20T06:19:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63529#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63529\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\\\/VEGF Bispecific LM-299\\\/MK-2010 in NSCLC at AACR 2026\",\"datePublished\":\"2026-04-20T06:16:13+00:00\",\"dateModified\":\"2026-04-20T06:19:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63529\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Clinical trial results\",\"HKG: 1177\",\"LaNova Medicines\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"Multi-specific antibodies\",\"NYSE: MRK\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63529#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63529\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63529\",\"name\":\"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\\\/VEGF Bispecific LM-299\\\/MK-2010 in NSCLC at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-20T06:16:13+00:00\",\"dateModified\":\"2026-04-20T06:19:09+00:00\",\"description\":\"Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299\\\/MK-2010, a PD-1\\\/VEGF bispecific antibody (BsAb) co-developed by its subsidiary LaNova Medicines Ltd and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate encouraging antitumor activity and a manageable safety profile in non-small cell lung cancer (NSCLC) patients, validating MSD's $3.3 billion licensing investment made in 2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63529#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63529\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63529#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\\\/VEGF Bispecific LM-299\\\/MK-2010 in NSCLC at AACR 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\/VEGF Bispecific LM-299\/MK-2010 in NSCLC at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299\/MK-2010, a PD-1\/VEGF bispecific antibody (BsAb) co-developed by its subsidiary LaNova Medicines Ltd and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate encouraging antitumor activity and a manageable safety profile in non-small cell lung cancer (NSCLC) patients, validating MSD's $3.3 billion licensing investment made in 2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63529","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\/VEGF Bispecific LM-299\/MK-2010 in NSCLC at AACR 2026","og_description":"Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299\/MK-2010, a PD-1\/VEGF bispecific antibody (BsAb) co-developed by its subsidiary LaNova Medicines Ltd and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate encouraging antitumor activity and a manageable safety profile in non-small cell lung cancer (NSCLC) patients, validating MSD's $3.3 billion licensing investment made in 2024.","og_url":"https:\/\/flcube.com\/?p=63529","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-20T06:16:13+00:00","article_modified_time":"2026-04-20T06:19:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63529#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63529"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\/VEGF Bispecific LM-299\/MK-2010 in NSCLC at AACR 2026","datePublished":"2026-04-20T06:16:13+00:00","dateModified":"2026-04-20T06:19:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63529"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Clinical trial results","HKG: 1177","LaNova Medicines","Merck Sharp &amp; Dohme","MSD","Multi-specific antibodies","NYSE: MRK","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63529#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63529","url":"https:\/\/flcube.com\/?p=63529","name":"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\/VEGF Bispecific LM-299\/MK-2010 in NSCLC at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-20T06:16:13+00:00","dateModified":"2026-04-20T06:19:09+00:00","description":"Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299\/MK-2010, a PD-1\/VEGF bispecific antibody (BsAb) co-developed by its subsidiary LaNova Medicines Ltd and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate encouraging antitumor activity and a manageable safety profile in non-small cell lung cancer (NSCLC) patients, validating MSD's $3.3 billion licensing investment made in 2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63529#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63529"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63529#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical Reports 55% Response Rate for PD-1\/VEGF Bispecific LM-299\/MK-2010 in NSCLC at AACR 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63529"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63529\/revisions"}],"predecessor-version":[{"id":63531,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63529\/revisions\/63531"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}